Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines

被引：22

作者：

Axelsson, Fredrika ^{[1
]}

Adler, Stuart P. ^{[2
]}

Lamarre, Alain ^{[3
]}

Ohlin, Mats ^{[1
]}

机构：

[1] Lund Univ, Dept Immunotechnol, SE-22184 Lund, Sweden

[2] Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA

[3] INRS Inst Armand Frappier, Inst Natl Rech Sci, Immunovirol Lab, Quebec City, PQ, Canada

来源：

VACCINE | 2007年 / 26卷 / 01期

关键词：

live attenuated vaccine; neutralization epitope; subunit vaccine;

D O I：

10.1016/j.vaccine.2007.10.048

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Glycoprotein B (gB) is a major component in several vaccines that are under development for prevention of disease by cytomegalovirus. It contains multiple determinants that are targets for neutralizing antibodies. One of them is site I of antigenic domain 2 (AD-2). The epitope, defined by short peptides, is quite conserved between different isolates. However, it is poorly immunogenic in natural infection. In this study we investigated the extent to which different vaccines, attenuated live Towne vaccine with or without priming with a canarypox virus coding for gB, or a recombinant gB vaccine adjuvanted with MF59, induced antibodies to this epitope. As in natural infection only a fraction of all. subjects developed antibody responses against site I of AD-2 following vaccination. We suggest that strategies that enhance immunogenicity of this epitope will improve vaccine efficacy. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：41 / 46

页数：6

共 26 条

[1] A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne) [J].

Adler, SP ;

Plotkin, SA ;

Gonczol, E ;

Cadoz, M ;

Meric, C ;

Ben Wang, JA ;

Dellamonica, P ;

Best, AM ;

Zahradnik, J ;

Pincus, S ;

Berencsi, K ;

Cox, WI ;

Gyulai, Z .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :843-846

[2] CELL-SURFACE EXPRESSION OF HUMAN CYTOMEGALOVIRUS (HCMV) GP55-116 (GB) - USE OF HCMV-RECOMBINANT VACCINIA VIRUS-INFECTED CELLS IN ANALYSIS OF THE HUMAN NEUTRALIZING ANTIBODY-RESPONSE [J].

BRITT, WJ ;

VUGLER, L ;

BUTFILOSKI, EJ ;

STEPHENS, EB .

JOURNAL OF VIROLOGY, 1990, 64 (03) :1079-1085

[3] Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein B antibody transfer in guinea pigs [J].

Chatterjee, A ;

Harrison, CJ ;

Britt, WJ ;

Bewtra, C .

JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (11) :1547-1553

[4] THE OUTCOME OF CONGENITAL CYTOMEGALOVIRUS-INFECTION IN RELATION TO MATERNAL ANTIBODY STATUS [J].

FOWLER, KB ;

STAGNO, S ;

PASS, RF ;

BRITT, WJ ;

BOLL, TJ ;

ALFORD, CA .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (10) :663-667

[5] AN ELISA USING RECOMBINANT PROTEINS FOR THE DETECTION OF NEUTRALIZING ANTIBODIES AGAINST HUMAN CYTOMEGALOVIRUS [J].

KROPFF, B ;

LANDINI, MP ;

MACH, M .

JOURNAL OF MEDICAL VIROLOGY, 1993, 39 (03) :187-195

[6] Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus [J].

Lantto, J ;

Fletcher, JM ;

Ohlin, M .

VIROLOGY, 2003, 305 (01) :201-209

[7] A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B [J].

Lantto, J ;

Fletcher, JM ;

Ohlin, M .

JOURNAL OF GENERAL VIROLOGY, 2002, 83 :2001-2005

[8] Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis [J].

Maidji, E ;

McDonagh, S ;

Genbacev, O ;

Tabata, T ;

Pereira, L .

AMERICAN JOURNAL OF PATHOLOGY, 2006, 168 (04) :1210-1226

[9] HUMAN MONOCLONAL-ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS [J].

MASUHO, Y ;

MATSUMOTO, YI ;

SUGANO, T ;

FUJINAGA, S ;

MINAMISHIMA, Y .

JOURNAL OF GENERAL VIROLOGY, 1987, 68 :1457-1461

[10] Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response [J].

McLean, GR ;

Olsen, OA ;

Watt, IN ;

Rathanaswami, P ;

Leslie, KB ;

Babcook, JS ;

Schrader, JW .

JOURNAL OF IMMUNOLOGY, 2005, 174 (08) :4768-4778

← 1 2 3 →